These findings were presented today at the International Society for Cellular Therapy (ISCT) annual meeting in Berlin, Germany. The Pall Corporation (NYSE: PLL) Filter Harvest System was found to have the potential to become a valuable tool to help realize the promise of regenerative medicine, a field that scientists believe could produce significant breakthroughs in the treatment of heart disease, cancer, diabetes, bone injury and many other acute and chronic conditions.
Lisa Bradbury, Ph.D., Director, R&D Cell Therapy, Pall Life Sciences, presented data comparing the Pall Filter Harvest System to a traditional open-system, density gradient, centrifuge-based method for isolation of mononuclear cells (MNC) from whole blood. The Pall Filter Harvest System was found to significantly reduce processing time; it can be performed in less than 15 minutes compared to an average processing time of about 2.5 to 4 hours with the Ficoll gradient technique. The Filter Harvest System also exhibited higher yield of MNCs for significantly better recovery (60 to 95 percent) than the Ficoll method.
The Pall Filter Harvest system can be used as a closed system that adheres to Good Manufacturing Practice (cGMP), furthering the ability to comply with increasingly stringent regulations for safe, reproducible and efficacious cell products. In addition to rapid processing, the Pall system can be performed at point of use (operating room). It does not require the addition of laboratory equipment or trained technicians, as the method is easy to learn and use.
"Researchers and companies working in cell therapy expressed the need to find better and easi
'"/>
Source:University of Utah